Shares of Fulcrum Therapeutics Plunge After Study Results
Recently, shares of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) took a significant hit, plunging 61.1% after the company announced disappointing findings from its phase III REACH study. This study focused on losmapimod, a potential treatment for individuals diagnosed with facioscapulohumeral muscular dystrophy (FSHD), a rare and debilitating disorder.
Currently, there are no approved treatments for FSHD.
The analysis from the study revealed that losmapimod did not achieve its primary objectives. Specifically, it showed no significant improvement from the baseline in relative surface area (RSA), a key measure of reachable workspace (RWS), when compared to a placebo after 48 weeks of treatment.
In addition, the study fell short of meeting statistically significant outcomes for its secondary endpoints as well.
This year, Fulcrum's shares have faced a striking decline, dropping by 49%, while the industry has only experienced a minor decrease of 0.8%.
Key Takeaways from the REACH Study Results
The data from the REACH study indicated that treatment with losmapimod led to a small improvement of 0.013 in RSA, while the placebo group had a slightly better improvement of 0.010 in RWS at the 48-week assessment—which highlights the shortfall in achieving the study's primary endpoint.
Moreover, participants on losmapimod saw a concerning increase of 0.42% in muscle fat infiltration, compared to an increase of 0.57% in the placebo group during the same evaluation period.
On a brighter note, there were improvements observed in abductor muscle strength; those receiving losmapimod experienced a 9.63% enhancement, which significantly outperformed the 2.24% improvement in the placebo group.
Unfortunately, results from two patient-reported secondary endpoints did not show any significant differences in either treatment group.
In light of the disappointing outcomes from the REACH study, Fulcrum has decided to discontinue the development of losmapimod for FSHD treatment.
What Lies Ahead for Fulcrum Therapeutics
Moving forward, Fulcrum is shifting its focus to another promising candidate, pociredir, which is in the early stages of development for treating sickle cell disease (SCD), a genetic blood disorder. The ongoing phase Ib PIONEER study is evaluating pociredir's effectiveness in this demographic.
The FDA has granted pociredir both Fast Track and Orphan Drug designations, underscoring its potential to address crucial unmet medical needs in sickle cell treatment. Should the development prove successful, pociredir could significantly bolster Fulcrum's standing in the biotech sector.
As of the end of June, Fulcrum reported a strong cash position with $273.8 million in cash, cash equivalents, and marketable securities, which the company intends to use to advance pociredir and other projects in its pipeline.
Comparative Performance Among Industry Stocks
At present, Fulcrum boasts a notable Zacks Rank #1 (Strong Buy), reflecting solid market confidence despite recent setbacks.
Other highly rated stocks in the biotech sector include Illumina, Inc. (NASDAQ: ILMN) and Krystal Biotech, Inc. (NASDAQ: KRYS), both of which also share a Zacks Rank #1 currently.
In the past two months, Illumina's earnings estimates for 2024 have shot up from $1.18 to $3.62 per share, while projections for 2025 grew from $2.93 to $4.43. Despite a year-to-date decline of 9.3%, ILMN has consistently beaten earnings estimates over the last four quarters with an average surprise of 463.46%.
Meanwhile, Krystal Biotech's earnings outlook for 2024 increased from $1.98 to $2.38, along with a rise in 2025 estimates from $4.33 to $7.31. Notably, KRYS stocks have surged 57.7% year to date, and they’ve realized an average surprise of 45.95% from earnings estimates in three of their last four quarters.
Frequently Asked Questions
What caused Fulcrum's stock to drop?
Fulcrum's stock fell sharply due to disappointing results from the REACH study, which aimed to assess its treatment for FSHD.
What is losmapimod?
Losmapimod is a therapeutic candidate developed by Fulcrum Therapeutics intended to treat facioscapulohumeral muscular dystrophy (FSHD).
Are there any approved treatments for FSHD?
Currently, there are no approved treatment options for FSHD.
What is pociredir?
Pociredir is another candidate in Fulcrum's pipeline that is being evaluated for its effectiveness in treating sickle cell disease.
What financial position is Fulcrum in?
Fulcrum Therapeutics currently has $273.8 million in cash and equivalents, which they plan to invest in further development efforts.
